Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 25, Issue 7, 2012, Pages 1135-1141

  Mijal, Renée S ^a,b   Holzman, Claudia B ^a   Rana, Sarosh ^c   Karumanchi, S Ananth ^c   Wang, Jianling ^a   Sikorskii, Alla ^d  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Endoglin; Placental growth factor; Preeclampsia; Small for gestational age; Soluble fms like tyrosine kinase 1

Indexed keywords

ANGIOGENIC MARKER; BIOLOGICAL MARKER; PLACENTAL GROWTH FACTOR; SOLUBLE ENDOGLIN; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; GESTATION PERIOD; GESTATIONAL AGE; HUMAN; PREECLAMPSIA; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; RISK ASSESSMENT; SMALL FOR DATE INFANT; SMOKING;

ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; NEOVASCULARIZATION, PHYSIOLOGIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, SECOND; PREMATURE BIRTH; RECEPTORS, CELL SURFACE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84862868665     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2011.625458     Document Type: Article

References (33)

1. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008;371:75-84.
2. Institute of Medicine. Preterm birth: Causes, consequences, and prevention brief report: Institute of Medicine of the National Academies, 2006.
3. Holzman C, Bullen B, Fisher R, Paneth N, Reuss L; Prematurity Study Group. Pregnancy outcomes and community health: the POUCHstudy of preterm delivery. Paediatr Perinat Epidemiol 2001;15 Suppl 2:136-158. (Pubitemid 33719624)
4. Silasi M, Cohen B, Karumanchi SA, Rana S. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am 2010;37:239-253.
5. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-649. (Pubitemid 43865232)
6. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-683. (Pubitemid 38364626)
7. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658. (Pubitemid 36278583)
8. Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9-23.
9. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, Crombleholme WR, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 2005;90:4895-4903. (Pubitemid 41159388)
10. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003;1: 1356-1370.
11. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, Karumanchi SA, Thadhani R, et al. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005;26:563-573. (Pubitemid 40916309)
12. Demir R, Seval Y, Huppertz B. Vasculogenesis and angiogenesis in the early human placenta. Acta Histochem 2007;109:257-265. (Pubitemid 46962081)
13. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, et al.; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355: 992-1005. (Pubitemid 44343543)
14. Meis PJ, Goldenberg RL, Mercer BM, Iams JD, Moawad AH, Miodovnik M, Menard MK, et al. The preterm prediction study: risk factors for indicated preterm births. Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. Am J Obstet Gynecol 1998;178:562-567.
15. Ananth CV, Vintzileos AM. Maternal-fetal conditions necessitating a medical intervention resulting in preterm birth. Am J Obstet Gynecol 2006;195:1557-1563. (Pubitemid 44792631)
16. Salafia CM, Lopez-Zeno JA, Sherer DM, Whittington SS, Minior VK, Vintzileos AM. Histologic evidence of old intrauterine bleeding is more frequent in prematurity. Am J Obstet Gynecol 1995;173:1065-1070.
17. Chaiworapongsa T, Romero R, Tarca A, Kusanovic JP, Mittal P, Kim SK, Gotsch F, et al. A subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study. J Matern Fetal Neonatal Med 2009;22:1122-1139.
18. Smith GC, Crossley JA, Aitken DA, Jenkins N, Lyall F, Cameron AD, Connor JM, Dobbie R. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 2007;109:1316-1324. (Pubitemid 46869870)
19. Mijal RS, Holzman CB, Rana S, Karumanchi SA, Wang J, Sikorskii A. Midpregnancy levels of angiogenic markers in relation to maternal characteristics. Am J Obstet Gynecol 2011;204:244.e1-244.12.
20. Levine RJ, Hauth JC, Curet LB, Sibai BM, Catalano PM, Morris CD, DerSimonian R, et al. Trial of calcium to prevent preeclampsia. N Engl J Med 1997;337:69-76. (Pubitemid 27284391)
21. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000;183:S1-S22.
22. Oken E, Kleinman KP, Rich-Edwards J, Gillman MW. A nearly continuous measure of birth weight for gestational age using a United States national reference. BMC Pediatr 2003;3:6.
23. Jeyabalan A, Powers RW, Durica AR, Harger GF, Roberts JM, Ness RB. Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia. Am J Hypertens 2008;21:943-947.
24. Cnattingius S. The epidemiology of smoking during pregnancy: smoking prevalence, maternal characteristics, and pregnancy outcomes. Nicotine Tob Res 2004;6 Suppl 2:S125-S140. (Pubitemid 38678838)
25. Hutcheon JA, Platt RW. The missing data problem in birth weight percentiles and thresholds for "small-for-gestational-age". Am J Epidemiol 2008;167:786-792. (Pubitemid 351451740)
26. Lindheimer MD, Romero R. Emerging roles of antiangiogenic and angiogenic proteins in pathogenesis and prediction of preeclampsia. Hypertension 2007;50:35-36. (Pubitemid 46986005)
27. Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 2009;24:147-158.
28. Norman JE, Morris C, Chalmers J. The effect of changing patterns of obstetric care in Scotland (1980-2004) on rates of preterm birth and its neonatal consequences: perinatal database study. PLoS Med 2009;6:e1000153.
29. Barros FC, Velez Mdel P. Temporal trends of preterm birth subtypes and neonatal outcomes. Obstet Gynecol 2006;107:1035-1041.
30. Kingdom JC, Kaufmann P. Oxygen and placental villous development: origins of fetal hypoxia. Placenta 1997;18:613-21; discussion 623. (Pubitemid 27448416)
31. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007;50:137-142. (Pubitemid 46986022)
32. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and smallfor- gestational age. J Matern Fetal Neonatal Med 2008;21:279-287. (Pubitemid 351652513)
33. Asvold BO, Vatten LJ, Romundstad PR, Jenum PA, Karumanchi SA, Eskild A. Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction. Am J Epidemiol 2011;173:630-639.